<DOC>
	<DOCNO>NCT02998671</DOCNO>
	<brief_summary>The study design primarily assess preliminary efficacy safety CJM112 patient moderate severe inflammatory acne determine CJM112 adequate clinical profile clinical development . In addition , sustainability response dose relationship explore .</brief_summary>
	<brief_title>Study Efficacy Safety CJM112 Patients With Moderate Severe Inflammatory Acne</brief_title>
	<detailed_description />
	<mesh_term>Acne Vulgaris</mesh_term>
	<criteria>Male female subject age 18 45 year age include , otherwise good health determine medical history , physical examination , vital sign , ECGs laboratory test screen . Body weight 50 120 kg , inclusive screening . Papulopustular acne vulgaris 25 100 facial inflammatory lesion ( papule , pustule nodule ) , presence noninflammatory lesion ( open close comedo ) face screen baseline . No 5 facial inflammatory nodule screen baseline . Investigator 's Global assessment ( IGA ) score least moderate ( 3 ) acne severity face screen baseline . Appropriate wash period require investigational drug , oral/systemic treatment acne , systemic lesional inject ( acne ) corticosteroid systemic immunomodulators , systemic hormonal treatment , previous treatment biologics , oral retinoids ( particular isotretinoin ) topical antiacne treatment . Use facial medium depth chemical peel ( exclude home regimen ) within 3 month prior baseline . Any live vaccine ( include nasalspray flu vaccine ) start 6 week baseline . Any form acne Any severe , progressive uncontrolled medical psychiatric condition factor randomization judgment investigator prevents patient participate study . History hypersensitivity allergy investigational compound/compound class use study . Active systemic infection ( common cold ) 2 week prior baseline . History severe systemic Candida infection evidence Candidiasis 2 week prior baseline . Evidence active tuberculosis screening . All patient test tuberculosis status use blood test ( QuantiFERONÂ®TB ( Tuberculosis ) Gold InTube ) . Patients evidence tuberculosis may enter trial afteradequate treatment start accord local regulation . Patients know active Crohn 's disease History immunodeficiency disease , include positive HIV ( ELISA Western blot ) test result screening . A positive Hepatitis B surface antigen Hepatitis C test result screen Pregnant nursing ( lactate ) woman , pregnancy define state female conception termination gestation , confirm positive Human chorionic gonadotropin ( HCG ) laboratory test . WOCBP , define woman physiologically capable become pregnant , unless use highly effective method contraception dose 13 week stop medication . Other protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Acne , inflammatory acne , efficacy , safety , PK</keyword>
</DOC>